Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: September 14, 2026 (Earliest event reported)
Signature Date: September 17, 2026
Context: The filing discloses an investor presentation delivered at the H.C. Wainwright 28th Annual Global Investor Conference and announces the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory and corporate events rather than financial performance data.
Material Changes and Events
- Regulatory Submission: On September 17, 2026, the Company resubmitted its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film, indicated for the treatment of Type I allergic reactions, including anaphylaxis.
- Investor Communications: The Company furnished an investor presentation to institutional investors and analysts at the H.C. Wainwright conference on September 14, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference an investor presentation and a press release regarding the NDA resubmission. The Company notes that the information provided may be amended or updated in future filings.
Legal Disclaimer: The information in Item 7.01 (including the investor presentation) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks: The filing does not explicitly detail new risks, though the resubmission of an NDA implies prior regulatory review outcomes that necessitated a new submission.
Investor Verification Checklist
- Verify the status and expected timeline for the FDA's review of the resubmitted Anaphylm™ NDA.
- Review the attached Exhibit 99.2 (Investor Presentation) for updated clinical data or commercial projections not detailed in the 8-K text.
- Confirm the specific reasons for the NDA resubmission by reviewing the September 17, 2026 press release (Exhibit 99.1).
- Monitor future filings for any updates to the regulatory status or changes in the Company's financial outlook resulting from this event.